Core Insights - Sessa Capital disclosed a significant purchase of Sotera Health, acquiring 10,630,381 shares valued at approximately $175.80 million based on quarterly average pricing [1][2] Company Overview - Sotera Health is a prominent provider of sterilization and lab testing services, essential for healthcare and life sciences supply chains, leveraging specialized technology and regulatory expertise [5][8] - The company reported a market capitalization of $4.0 billion, with a revenue of $1.2 billion and a net income of $77.9 million for the trailing twelve months [4] Financial Performance - Sotera Health achieved revenue of about $1.16 billion and an adjusted EBITDA close to $600 million last year, reflecting 20 years of consistent growth [9] - The stock price of Sotera Health was $13.99, representing an 18% increase over the past year, slightly outperforming the S&P 500's 15% gain during the same period [7] Investment Implications - The recent stake acquired by Sessa Capital represents nearly 7% of its 13F reportable assets under management, indicating a significant commitment to Sotera Health [7] - Despite the strong fundamentals, the stock has faced downward pressure due to litigation risks, high leverage, and regulatory concerns, alongside a recent secondary offering that introduced a technical overhang [9][10] - Long-term investors are focused on the company's ability to sustain mid-single-digit growth and manage litigation risks, which could close the gap between actual performance and investor perception [11]

Core Insights - MIG Capital disclosed a reduction in its holdings of Sotera Health, selling 2,262,292 shares valued at approximately $37.41 million [1][2] - The total position value for Sotera Health declined by $31.83 million at the end of the fourth quarter of 2025, reflecting both trading and share price changes [2] Company Overview - Sotera Health is a leading provider of sterilization and laboratory services, supporting critical supply chains in healthcare, pharmaceuticals, and food safety [5] - The company operates a service-based business model generating revenue through sterilization, laboratory testing, and consulting for regulated industries [8] - As of the latest data, Sotera Health's market capitalization is $3.8 billion, with a revenue of $1.16 billion and a net income of $77.95 million for the trailing twelve months [4] Financial Performance - In 2025, Sotera Health achieved a 5.7% increase in sales to $1.16 billion, while adjusted EBITDA rose by 8.2% to approximately $594 million [6] - The net income nearly doubled from the previous year to $78 million, indicating significant progress on the bottom line [6] - The company expects revenue growth between 5% and 6.5% in 2026, with adjusted EBITDA projected to grow between 5.5% and 7% [10] Market Position - Despite the reduction in holdings, Sotera Health still represents nearly 6% of MIG Capital's portfolio assets, indicating continued confidence in the company [7] - Sotera Health shares were priced at $13.41, reflecting an 18% increase over the past year, slightly underperforming the S&P 500's approximately 20% gain [7] - The company serves a diverse range of clients, including medical device manufacturers, pharmaceutical companies, and food/agricultural producers across North America and Europe [8]

Company Overview - Sotera Health is a leading provider of sterilization and laboratory testing solutions, serving critical sectors such as healthcare and pharmaceuticals [6] - The company operates with a diversified portfolio of services to meet regulatory and safety requirements for a global client base, including medical device manufacturers and pharmaceutical companies [9] Financial Performance - Sotera Health reported a total revenue of $1.16 billion for the trailing twelve months (TTM) [4] - The net income for the same period was $77.95 million, with a significant year-over-year increase [11] - The company achieved its 20th consecutive year of revenue growth, with net revenues rising nearly 6% in 2025 and adjusted EBITDA climbing 8% to $594 million [11] - Management has guided for a revenue increase of 5% to 6.5% in 2026, alongside adjusted EBITDA growth of 5.5% to 7.0% [11] Stock Performance - As of February 17, 2026, shares of Sotera Health were priced at $17.09, reflecting a nearly 30% increase over the past year, outperforming the S&P 500 by 14.86 percentage points [8] - The reduction in Ananym Capital Management's stake in Sotera Health lowered its position to 8.65% of the fund's 13F reportable assets under management (AUM) as of December 31, 2025 [8] Market Position - Sotera Health operates mission-critical sterilization and testing infrastructure that is essential for medical device and pharmaceutical companies, making it a non-speculative investment [12] - The company has improved cash flow, reduced leverage to 3.2 times adjusted EBITDA, and strengthened liquidity [12] Investment Perspective - The modest reduction in Ananym Capital Management's position is viewed as risk management following a strong performance rather than a loss of confidence in Sotera Health's business model [10] - Long-term investors are encouraged to focus on the company's consistent revenue growth over two decades in a sector where reliability is crucial [13]

Core Insights - Sotera Health reported a total revenue increase of 5.7% in 2025 to $1.164 billion, with a 5.2% increase on a constant-currency basis [5] - The company expects continued revenue and EBITDA growth in 2026, projecting total revenue between $1.233 billion and $1.251 billion, representing 5% to 6.5% constant-currency growth [15] Financial Performance - Nelson Labs' Q4 revenue increased by 2.3% to $55 million, with segment income rising 1.9% to $18 million [1] - Nordion's Q4 revenue declined by 12.3% to $50 million, with segment income falling 18.9% to $29 million [1] - Sterigenics experienced a Q4 revenue growth of 10.6% to $198 million, with segment income rising 10.4% to $110 million [2] - Sotera Health's Q4 revenue was $303 million, up 4.6% year over year, with adjusted EBITDA increasing 2.7% to $157 million [4] Operational Highlights - Customer satisfaction exceeded 80%, and cross-business-unit customer revenue growth was 9% year over year [7] - Sterigenics delivered approximately 8% constant-currency revenue growth for 2025, while Nordion achieved about 9% constant-currency revenue growth [7] Strategic Initiatives - The company is investing in an X-ray facility project as part of a long-term strategy to enhance sterilization services [8] - Management noted that the Sterigenics commercial segment has been "choppy" since 2020-2021, indicating challenges in that area [9] Balance Sheet and Governance - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in $13 million of annual interest savings [12] - Liquidity at year-end included about $345 million of unrestricted cash and nearly $600 million of revolver capacity, totaling approximately $940 million [13] - Governance changes included the appointment of a lead independent director and a legal leadership transition [14] 2026 Guidance - Interest expense is expected to be between $135 million and $145 million, with adjusted EPS projected at $0.93 to $1.01 [17] - Capital expenditures are anticipated to be between $175 million and $225 million, with no M&A assumed in the guidance [17]